9 recruiting, 6 unknown, 5 completed, 3 not yet recruiting. 25 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 25 | Recruiting 9, Unknown 6, Completed 5, Not yet recruiting 3, Active not recruiting 1, Withdrawn 1 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration FSN+Vitamin supplement, Vitamin Supplements - Age - Related Macular Degeneration (AMD) | Early Phase 1 | Not yet recruiting | Zhiming Yan | 38 | 2026-07-07 | 2025-08-13 |
| Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy AGX-08-L, AGX-08-H, AGX-08-S - Geographic Atrophy | Early Phase 1 | Not yet recruiting | Zhongmou Therapeutics | 24 | 2026-07-01 | 2026-07-31 |
| First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration AXV-101 - Bardet-Biedl Syndrome 1, Retinal Degeneration | Early Phase 1 | Recruiting | Axovia Therapeutics | 12 | 2026-06-26 | 2026-08-04 |
| UGX202 Injection in Patients With Advanced Retinitis Pigmentosa UGX202 injection - Retinitis Pigmentosa (RP) | Early Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | 6 | 2026-01-01 | 2025-12-31 |
| Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system - Retinopathy, Retinal Vein Occlusion | Early Phase 1 | Recruiting | MediBeacon | 10 | 2025-11-06 | 2026-02-04 |
| An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease HG005 - Stargardt Disease Type 1 (STGD1) | Early Phase 1 | Recruiting | HuidaGene Therapeutics Co., Ltd. | 6 | 2025-08-20 | 2025-08-27 |
| A Study of LX107 Gene Therapy in AIPL1-IRD Patients LX107 Injection - Retinal Dystrophy | Early Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 13 | 2025-07-15 | 2026-03-10 |
| The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma occupational therapy interventions for low vision care - Age-Related Macular Degeneration | Early Phase 1 | Recruiting | MCPHS University | 50 | 2025-04-22 | 2026-05-12 |
| Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1 - Retinal Edema | Early Phase 1 | Unknown | Tanta University | 100 | 2024-12-01 | 2024-03-05 |
| Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon Suprachoroidal triamcinolone acetonide injection - Macular Edema (ME), Non Infectious Uveitis | Early Phase 1 | Recruiting | University of Baghdad | 20 | 2024-09-01 | 2025-08-28 |
| Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis IVB102 Injection - Retinoschisis, Retinal Disease | Early Phase 1 | Active not recruiting | InnoVec Biotherapeutics Inc. | 18 | 2024-03-08 | 2025-04-30 |
| Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients ZM-02-L, ZM-02-H, ZM-02-S - Retinitis Pigmentosa | Early Phase 1 | Recruiting | Zhongmou Therapeutics | 12 | 2024-02-25 | 2026-03-31 |
| Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS) JWK002 - X Linked Retinoschisis | Early Phase 1 | Recruiting | West China Hospital | 12 | 2023-11-17 | 2025-02-07 |
| Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa ZVS203e - Retinitis Pigmentosa | Early Phase 1 | Recruiting | Peking University Third Hospital | 9 | 2023-09-12 | 2026-10-15 |
| Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients ZM-01-L, ZM-01-H - X-linked Retinoschisis | Early Phase 1 | Completed | Zhongmou Therapeutics | 2 | 2022-09-25 | 2026-03-31 |
| Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients Longvida curcumin, placebo - Age Related Macular Degeneration | Early Phase 1 | Completed | University of Illinois at Chicago | 10 | 2020-11-01 | 2025-03-21 |
| The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients cannabis - Retinitis Pigmentosa, Retinal Degeneration | Early Phase 1 | Unknown | Hadassah Medical Organization | 50 | 2018-09-01 | 2021-02-12 |
| Treatment of RP and LCA by Primary RPE Transplantation Human primary Retinal Pigment Epithelial (HuRPE) cells - Leber Congenital Amaurosis, Retinitis Pigmentosa | Early Phase 1 | Unknown | Eyecure Therapeutics Inc. | 30 | 2018-08-01 | 2018-08-09 |
| Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation Vitamin A Palmitate - Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration | Early Phase 1 | Completed | National Eye Institute (NEI) | 9 | 2018-05-14 | 2025-04-16 |
| Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections Chlorhexidine, Povidine-Iodine - Age-related Macular Degeneration, Diabetic Vascular Diseases | Early Phase 1 | Unknown | MidAtlantic Retina | 100 | 2018-05-07 | 2018-06-27 |
Showing 20 of 25. Sign in to see all of them.
Macular Degeneration (9) · Retinitis Pigmentosa (6) · Macular Edema (3) · Retinoschisis (3) · Retinal Diseases (2) · Retinal Vein Occlusion (2) · Bardet-Biedl syndrome 1 (1) · Diabetic Angiopathies (1) · Diabetic Retinopathy (1) · Eye Diseases (1) · Geographic Atrophy (1) · Leber Congenital Amaurosis (1) · Marijuana Abuse (1) · Papilledema (1)
Eye Diseases (24) · Retinal Diseases (23) · Eye Diseases, Hereditary (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Retinal Dystrophies (6) · Macular Degeneration (5) · Cardiovascular Diseases (3) · Vascular Diseases (3) · Diabetes Complications (2) · Diabetes Mellitus (2) · Embolism and Thrombosis (2) · Endocrine System Diseases (2) · Nervous System Diseases (2)
Cannabidiol (1) · Cell Count (1) · Chlorhexidine (1) · Contraceptives, Oral (1) · Dronabinol (1) · Fluorescein (1) · Geritol (1) · Povidone-Iodine (1) · Ranibizumab (1) · Receptors, Antigen, B-Cell (1) · Triamcinolone Acetonide (1) · nabiximols (1) · relmapirazin (1) · retinol palmitate (1) · salicylhydroxamic acid (1)
Zhongmou Therapeutics (3) · Axovia Therapeutics (1) · Eyecure Therapeutics Inc. (1) · Glenn Jaffe (1) · Hadassah Medical Organization (1) · HuidaGene Therapeutics Co., Ltd. (1) · InnoVec Biotherapeutics Inc. (1) · MCPHS University (1) · MediBeacon (1) · MidAtlantic Retina (1) · National Eye Institute (NEI) (1) · Peking University Third Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Sun Yat-sen University (1) · Suzhou UgeneX Therapeutics Co., Ltd. (1)
China (11) · United States (6) · Israel (2) · Egypt (1) · Iraq (1) · United Kingdom (1)
Amin E Nawar, Lecturer (1) · Emily Y Chew, M.D. (1) · Fang Lu (1) · Glenn J Jaffe, MD (1) · Hadas Mechoulam, MD (1) · Jian Sun (1) · Liping Yang, MD (1) · Michelle Dowling, OTD (1) · Mordecai Rosner, MD (1) · Ningli Wang (1) · Prof Mariya Moosajee (1) · Qianying Gao, PHD (1) · Qinghuai Liu, M.D. (1) · Richard B Dorshow, PhD (1)
PMID 22183743, PMID 33221515, PMID 35469288, PMID 36438589, PMID 37315571, PMID 40604486